EGFR and non-small cell lung carcinoma: A retrospective study of 80 patients with NSCLC showed that, in 53.7% of patients who progressed after first-line therapy with first- or second-generation T790M mutation in EGFR-TKIs was found at the first rebiopsy, and subsequent rebiopsies increased the detection rate by 12.5%, 2.5%, 1.2%, and 1.2% [14].